retatrutide benefits clinical trial The power of three: Retatrutide's role in modern obesity and diabetes therapy Retatrutide Before and After: Doctor

problems related to the fallopian tubes, uterus, or cervix

The Roundhill GLP-1 & Weight Loss ETF (OZEM) is the worlds first GLP-1 ETF

If you develop a persistent, unexplained change in bowel habit particularly if you are aged 40 or over or have other risk factors your GP may wish to assess you in line with NICE guidance on suspected cancer (NG12), which sets out referral thresholds for persistent bowel changes

What the Recent Study Found In a 2024 Cell Metabolism study, patients taking atorvastatin (a commonly used statin) showed a nearly 50% drop in their levels of GLP-1, the hormone that GLP-1 agonists (Ozempic, Wegovy, etc.) mimic

A separate overview of leading GLP-1 weight loss programs for 2026 offers broader category context for consumers comparing telehealth access models